Andrew
Director
Dentistry
swedish dental AB
Sweden
Biography
Andy is a receptor pharmacologist who has studied GPCRs for 25 years. Andy is best known for his work on allosteric modulators of GPCRs, and he led the discovery of the first reported positive allosteric modulators of mu opioid receptors, delta opioid receptors, and D1 dopamine receptors. Andy has 14 years of pharmaceutical industry experience, ranging from biotech (EPIX Pharmaceuticals) to “big pharma” (BMS, Pfizer, and Eli Lilly) prior to joining Arvinas in 2016.
Research Interest
Dentistry
